Personalis - 7 Year Stock Price History | PSNL
Historical daily share price chart and data for Personalis since 2019 adjusted for splits and dividends. The latest closing stock price for Personalis as of September 17, 2026 is 16.23.
- The all-time high Personalis stock closing price was 51.02 on January 20, 2021.
- The Personalis 52-week high stock price is 18.89, which is 16.4% above the current share price.
- The Personalis 52-week low stock price is 4.96, which is 69.4% below the current share price.
- The average Personalis stock price for the last 52 weeks is 9.78.
| Personalis Historical Annual Stock Price Data | ||||||
|---|---|---|---|---|---|---|
| Year | Average Stock Price | Year Open | Year High | Year Low | Year Close | Annual % Change |
| 2026 | 10.3166 | 7.8500 | 18.3800 | 5.0400 | 16.2300 | 103.89% |
| 2025 | 5.9876 | 6.2700 | 11.2100 | 3.0000 | 7.9600 | 37.72% |
| 2024 | 2.9359 | 2.0400 | 6.3400 | 1.1500 | 5.7800 | 175.24% |
| 2023 | 2.0337 | 2.0100 | 4.1700 | 0.9300 | 2.1000 | 6.06% |
| 2022 | 5.4195 | 14.3000 | 14.3000 | 1.7800 | 1.9800 | -86.12% |
| 2021 | 23.5645 | 34.7800 | 51.0200 | 12.2400 | 14.2700 | -61.02% |
| 2020 | 17.7151 | 10.9100 | 44.0000 | 4.7500 | 36.6100 | 235.87% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $1.687B | $0.070B |
| Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| BridgeBio Pharma (BBIO) | United States | $13.352B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |